OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Friday, February 13th EUOK, MRNA, MELA, ZIPI, INSM, DFT

EUOKO GROUP INCORPORATED (OTCBB: EUOK) Detailed Quote: http://www.otcpicks.com/quotes/EUOK.php Euoko Group Inc. develops, markets and distributes scientifically-advanced, innovative skin treatments for luxury and mass markets. The luxury brand, Euoko, is the company's flagship brand. Euoko's current portfolio targets the most demanding class of luxury skin care customers and consists of 25 treatments spanning five collections that offer comprehensive solutions to such skin concerns as wrinkles, fine lines, under-eye dark circles, dark spots, pigmentation concerns, acne, oxidation, environmental exposure and skin fatigue. Euoko's well-appointed, understated primary and secondary packaging communicates innovation, science, modernism and clean sophistication, while reflecting the prestige positioning of the portfolio. Euoko's products are represented through premium distribution channels in more than twenty countries and territories. Since the introduction of its products in September 2007, Euoko has achieved retail partnerships with such premium department stores as Bergdorf Goodman, Saks Fifth Avenue, Neiman Marcus, La Rinascente (Italy), Ogilvy and Andrew's (Canada), Ludwig Beck (Germany), as well as such premier retailers as Bliss (USA), a subsidiary of Starwood Hotels and Resorts. Euoko's products are also sold globally through the company's internally-operated, multi-currency, multi-lingual website (www.euoko.com) and at 1.800.98.EUOKO (US/Canada). Euoko Group Inc. operates an investor communication website at www.euokogroup.com.

EUOK News: February 12 - Euoko to Unveil Six New Products in 2009 Euoko, a luxury brand of Euoko Group Inc. (OTCBB: EUOK), announced that it will introduce six new treatment products in 2009 to join its existing portfolio of 25 advanced skin treatments.

The first of these introductions will be that of the brand's much anticipated anti-aging treatment for the neck area, called Fractional Neck Lift Concentrate. Based on nine clinically-studied active ingredients, including multiple peptides, exotic plant extracts and D-Galacturonic Acid, this topical treatment addresses all aspects of skin aging in the neck area, including wrinkles, sagginess and overall loss of elasticity. This product will be available at Euoko's retail partners in more than 20 countries, including Bergdorf Goodman, Saks Fifth Avenue and Bliss spas in the United States, starting on May 6, 2009.

"Our vision of ongoing innovation remains strong for 2009, despite the global economic crisis. Our team and our retailers are most excited about these developments," said Brandon Truaxe, founder, President and CEO.

MDRNA INCORPORATED (NASDAQ: MRNA) "Up 116.69% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/MRNA.php MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in key therapeutic areas including oncology, metabolic disorders and inflammation. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company.

MRNA News: February 13 - Titan Resources Releases 'Norgold' Assay Results MDRNA, Inc. (Nasdaq: MRNA) announced that it has entered into an agreement with Roche (Swiss: ROG.SW) in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.

"We are pleased to have Roche recognize the value of our drug discovery platform," stated J. Michael French, President and Chief Executive Officer of MDRNA. "To have a portion of our platform in-licensed by Roche, a company with a significant effort in RNAi-based therapeutics, is a great testament to our intellectual property estate as well as the strong science being performed by our researchers. This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities. We look forward to working with Roche to capitalize on the platform capability we are licensing to them as part of this agreement." ELECTRO-OPTICAL SCIENCES INCORPORATED (NASDAQ: MELA) "Up 73.37% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/MELA.php Electro-Optical Sciences (EOS) is a medical device company focused on designing and developing a non-invasive, point-of-care instrument to assist in the early detection of melanoma. MelaFind features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. Using sophisticated algorithms, the data are then analyzed against a proprietary database of melanomas and benign lesions in order to provide information to assist in the determination of whether the lesion should be biopsied.

MELA News: February 13 - Electro-Optical Sciences Announces Positive Top-Line Results From Landmark MelaFind Pivotal Trial Company to File PMA Application With FDA; Largest Prospective Clinical Study Ever Conducted in Melanoma Detection; Company to Host Conference Call at 8:30 a.m. EST Friday Electro-Optical Sciences, Inc. (Nasdaq: MELA) ("EOS") announced positive top-line results of its pivotal trial of MelaFind, a non-invasive, point-of-care instrument to assist in the early detection of melanoma, the deadliest form of skin cancer. The blinded study, conducted at seven centers across the US, included 1,831 pigmented skin lesions from 1,383 patients, making this the largest prospective study ever conducted in melanoma detection. EOS is working to complete its Pre-Market Approval (PMA) application and expects to file it with the US Food and Drug Administration (FDA) shortly.

"MelaFind appears to be an excellent tool to help detect melanoma at the earliest, most treatable stage," said Gary D. Monheit, MD, Associate Clinical Professor of Dermatology at the University of Alabama in Birmingham and the lead investigator for the MelaFind pivotal trial. "With no cure for late stage melanoma, early detection is our best defense against this cancer, which has reached epidemic proportions." Prior to the start of the study, EOS and the FDA entered into a binding protocol agreement to stipulate the sensitivity and specificity endpoints that should be used to determine the safety and effectiveness of MelaFind.

MelaFind detected 112 of 114 (98% sensitivity; lower confidence bound of 95%) melanomas that were eligible and evaluable for primary sensitivity endpoint analysis, and 125 of 127 (98% sensitivity; lower confidence bound greater than 95%) melanomas overall. The protocol agreement calls for sensitivity endpoints of greater than 95% lower confidence bound(footnote 1).

MelaFind's specificity, the ability to accurately rule out disease, was significantly superior (9.5%) to that of the study dermatologists (3.7%), who are skin cancer experts (p-value less than 0.02). The protocol agreement calls for MelaFind to be more specific than the study physicians at a p-value(footnote 2) of less than 0.05.

Almost half of the melanomas in the study were melanoma in situ, the most curable yet most difficult form of melanoma to detect.

"These clinically compelling data suggest that MelaFind may help detect melanoma earlier, and more accurately differentiate many of the non-malignant lesions that mimic melanoma," said Darrell Rigel, MD, Clinical Professor of Dermatology at New York University Medical School. "This should lead to improved biopsy efficiency and help reduce the number of unnecessary biopsies, which can be painful and scarring." The skin cancer experts who participated in this study had previously made the decision to biopsy all 1,831 pigmented skin lesions prior to enrolling the patients in the MelaFind clinical trial.

In order to generate a comparison with dermatologists' ability to accurately detect melanoma, EOS conducted a parallel pilot readers' study with a different group of 39 dermatologists. Using images and clinical histories of 23 randomly-selected melanomas from the pivotal study, this group of dermatologists, on average, would have decided to biopsy only approximately 18 (80%) of the melanomas, whereas the MelaFind result would have led to a biopsy of 22 of the melanomas (biopsy sensitivity of 96%). A larger readers' study to provide additional data regarding the sensitivity of MelaFind relative to physicians will commence shortly. Data from these studies will be submitted to the FDA.

"We are extremely pleased with the outcome of the pivotal study and are now focused on completing our PMA to submit to the FDA as quickly as possible," said Joseph V. Gulfo, MD, President and CEO of EOS. "Our mission with MelaFind has always been to provide a useful tool to aid in detecting melanoma at its earliest, most curable stage. We look forward to discussing these data with the agency." The company chose the final classification algorithm based on its success at identifying melanomas in a series of large, blinded and sequential internal classifier selection studies conducted immediately prior to the analysis of the pivotal trial data. Including the pivotal trial, the MelaFind classifier successfully detected 430 of the 432 melanomas against which it was tested.

There were no adverse events associated with the use of MelaFind.

The FDA has notified EOS that the MelaFind PMA will receive Expedited Review once the application is submitted. EOS plans to submit the findings from the pivotal study and the readers' studies to peer-reviewed journals for publication.

MelaFind uses 10 different wavelengths of light to see where a clinician cannot -- up to 2.5 millimeters below the skin's surface. Using advanced algorithms, trained and developed on a database of 9,000 pigmented skin lesions and over 600 melanomas, including those from the pivotal study, the system provides an immediate result that informs the decision to biopsy.

Conference Call Information EOS will host a conference call on Friday, February 13 at 8:30 am EST. To participate, please dial 800-299-7089 fifteen minutes before the conference is scheduled to begin. Callers outside of the U.S. should dial +617-801-9714. The conference call passcode is "Electro Optical Sciences." A live webcast of this call will be available in the investor relations section of www.eosciences.com. A webcast replay of the call will be available for one month on the company's website, or until February 27, 2009 by dialing 888-286-8010. Callers outside of the US should dial +617-801-6888. The replay participant code is 52141913.

ABOUT MELANOMA Melanoma is the deadliest form of skin cancer, responsible for approximately 80% of skin cancer fatalities. The melanoma rate has continued to increase with an estimated 120,000 new cases projected in 2009. A recent National Cancer Institute report published in the July 10 online edition of the Journal of Investigative Dermatology indicates that annual incidence of melanoma among young adult Caucasian women rose 50% between 1980 and 2004. Melanoma is the most common cancer in women age 25 to 29 and the number one cancer killer of women age 30 to 35. Although no cure is currently available for advanced-stage melanoma, if caught early, melanoma is virtually 100% curable.

ZIPPI NETWORKS INCORPORATED (OTC: ZIPI) Detailed Quote: http://www.otcpicks.com/quotes/ZIPI.php Zippi Networks, Inc., headquartered in San Jose, Calif., has created a revolutionary business process (three US Patents Pending), together with the ease of hand-held mobile technology, social networking, and the ability to recycle that empowers a new generation of online sellers. Founded in 2006, Zippi promises to engage consumers with an easy toll free telephone number designed to allow everyone an easy hassle free way of selling items online; by phoning 1-877-GO-ZIPPI an item owner can receive a quick "mini appraisal" through the "Ask Zippi" appraisal system. Zippi connects this appraisal with the appropriate Zipster (eBay seller) which handles the entire transaction.

ZIPI News: February 12 - Zippi Kicks Off Mobile Commerce Strategy With Completion of New Apple iPhone Application Zippi Networks Inc. (OTC: ZIPI), turning America's "Clutter into Cash," announced the completion of a one of a kind application for Apple's iPhone, formally named "Zippi Cash." As firms such as Silicon Valley-based Kleiner Perkins Venture Fund have established 100 million dollar funds aimed specifically for iPhone application development, Zippi also recognizes the iPhone has created a new playing field for commerce, much like the beginning of the World Wide Web itself.

Zippi Cash is the first of several applications that Zippi has in the works. Zippi Cash encompasses the 3 US Patents pending within Zippi's business process and the release of this application provides an opportunity in the face of the economic crises facing many Americans and beyond. During this economic crisis, everyone is looking for extra cash and just about everyone has unused items they would like to turn into cash. According to eBay's research, there is approximately three thousand dollars ($3,000) of salable unused merchandise in the average household. With an open mobile platform, Zippi Cash stands alone in a category of mobile commerce products that can assist Americans, and those outside the US as well, to find out what items are hot sellers and what items are not.

Robert A. Rositano Jr., CEO Zippi Networks, Inc., stated, "This is a turning point in Zippi's lifecycle, allowing mobile access to data that can be invaluable for those in search of income and survival today. Ever wonder what your stuff is worth if you sold it online, with Zippi Cash now you can. Zippi searches millions of online and eBay transactions to provide a mini appraisal based on similar items sold, how quickly an item typically sells, how many similar items were listed in the past 30 days, and even what the high, low and average price was. In addition, Zippi Cash will give you the most common category, length of auction and best of all Zippi will assist you in scheduling an appointment for one of our Certified Online Sellers 'Zipster' to handle the selling for you." Zippi is submitting the application for Apple's approval this week and expects it to be available for download in the iTunes store within the next 2 - 3 weeks.

INSMED INCORPORATED (NASDAQ: INSM) "Up 17.35% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/INSM.php Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, visit www.insmed.com.

INSM News: February 12 - Merck & Co., Inc. Acquires Biologic Manufacturing Capabilities and Developmental Follow-on Biologics Portfolio from Insmed Merck & Co., Inc. announced that it has entered into a definitive agreement with Insmed Inc. (Nasdaq: INSM) to purchase Insmed's portfolio of follow-on biologic therapeutic candidates and its commercial manufacturing facilities located in Boulder, Colo. (Boulder facilities).

"Insmed's pipeline of follow-on biologic candidates presents the opportunity to expedite Merck's entry into the biologics marketplace as well as providing unique manufacturing resources and an experienced team of protein experts," said Frank K. Clyburn senior vice president and general manager Merck BioVentures. "This agreement represents a strong strategic fit for Merck as we aggressively expand and advance our portfolio of developmental follow-on biologics." Under the terms of the agreement, Merck, through an affiliate, will pay Insmed $130 million in cash to acquire all rights to the Boulder facilities and Insmed's pipeline of follow-on biologic candidates. The Boulder facilities comprise 50,000 square feet of biologics process development analytical laboratory and manufacturing facilities. Insmed's follow-on biologics portfolio includes INS-19, an investigational recombinant granulocyte-colony stimulating factor (G-CSF) that will be evaluated in Phase III clinical trials for its ability to prevent infections in patients with cancer receiving chemotherapy and INS-20, a pegylated recombinant G-CSF designed to allow for less frequent dosing, that is currently in Phase I clinical trials.

The agreement provides for initial payments of up to $10 million for INS-19 and INS-20. Merck will pay Insmed the remaining balance upon closing of the transaction, without any further milestone or royalty obligations. Merck plans to offer positions to staff at the Boulder facilities.

ABOUT MERCK BIOVENTURES In December 2008, Merck announced the establishment of a new division called Merck BioVentures, which capitalizes on the Company's industry-leading expertise in the manufacture of biologics, as well as proprietary technologies that streamline the production of protein-based therapies. By combining Merck's traditional strengths with the latest scientific innovations in protein manufacturing, Merck BioVentures will position the Company as a leader in the emerging field of follow-on biologics and provides a strong foundation for the development of novel protein therapeutics.

ABOUT MERCK Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.

DUPONT FABROS TECHNOLOGY (NYSE: DFT) "Up 12.00% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/DFT.php DuPont Fabros Technology, Inc. is a real estate investment trust (REIT) and leading owner, developer, operator and manager of wholesale data centers. The Company's data centers are highly specialized, secure facilities used primarily by national and international technology companies to house, power and cool the computer servers that support many of their most critical business processes. DuPont Fabros Technology, Inc. is headquartered in Washington, DC.

DFT News: February 11 - DuPont Fabros Technology, Inc. Reports Fourth Quarter and Year 2008 Results Provides Financing, Leasing and Dividend Updates DuPont Fabros Technology, Inc. (NYSE: DFT) reported results for the fourth quarter and year ended December 31, 2008. The results for 2007 are not provided in this earnings release as they are not comparable due to the Company's IPO on October 24, 2007. All per share results are reported on a fully diluted basis.

Hossein Fateh, President and Chief Executive Officer of the Company, said, "We delivered solid results for the year with revenues of $173.7 million, net income of $19.1 million and Funds from operations ("FFO") of $1.30 per share. Additionally, we have started strong in 2009 with the successful completion of several financing and leasing transactions." Highlights * Obtained $150.0 million of new debt via the ACC4 loan accordion feature on February 10, 2009.

* Paid off entire $135.1 million CH1 construction loan on February 10, 2009 eliminating debt maturities until August 2011 assuming extensions are exercised.

* Obtained $30.0 million of new debt on February 6, 2009 to complete ACC5.

* Restarted development of ACC5 in Ashburn, Virginia with expected completion in third quarter of 2009.

* Executed six new leases and pre-leases totaling 14.4 megawatts at facilities in Ashburn, Virginia and Elk Grove Village, Illinois in the fourth quarter 2008 and to date in the first quarter 2009, which represents approximately $340 million of contract value over the respective lease terms. ACC4 is now 94% leased and ACC5 is now 57% pre-leased.

Fourth Quarter 2008 For the quarter ended December 31, 2008, the Company reported net income of $3.5 million, or $0.10 per share compared to $4.1 million or $0.12 per share for the third quarter of 2008. FFO for the quarter ended December 31, 2008 was $20.1 million, or $0.30 per share, while Adjusted FFO ("AFFO") was $14.1 million, or $0.21 per share. Both FFO and AFFO were in line with the high end of the Company's expectations. FFO for the fourth quarter of 2008 decreased $0.8 million, or $0.01 per share, as compared to the third quarter of 2008 as a result of increased interest expense due to the temporary suspension of the Company's development projects and the placement of CH1 into service on August 1, 2008. Revenues increased 10.7%, or $4.6 million, to $47.5 million for the fourth quarter of 2008 over the third quarter of 2008 primarily due to one-time completed ancillary projects included in other revenue.

Year Ended December 31, 2008 For the year ended December 31, 2008, the Company reported net income of $19.1 million, or $0.54 per share. FFO for the year ended December 31, 2008 was $86.6 million, or $1.30 per share, while AFFO was $54.1 million, or $0.81 per share.

Portfolio Update/Status In the fourth quarter of 2008, the Company executed three new leases at its data center facilities: A) Two leases were signed at the Company's CH1 facility in Elk Grove Village, Illinois, comprising 1.7 megawatts of critical load, 12,556 raised square feet and lease terms of five and ten years comprising 9.5% of critical load at Phase I of CH1; B) The first pre-lease in Phase I of ACC5 in Ashburn, Virginia was executed, comprising 1.3 megawatts of critical load, 6,318 raised square feet and a lease term of ten years comprising 7.3% of the critical load.

Subsequent to the fourth quarter of 2008, the Company executed three additional leases at its facilities: A) One lease was signed at ACC4 in Ashburn, Virginia, representing 2.275 megawatts of critical load and 11,000 raised square feet with a lease term of 10 years; B) Two pre-leases were signed at ACC5 comprising 9.1 megawatts of critical load and 44,000 raised square feet with lease terms exceeding 12 years. The two pre-leases represent 50% of the facility's critical load.

C) In total, the fourth quarter 2008 and first quarter 2009 leases signed to date comprise 14.4 megawatts of critical load, 73,874 raised square feet and represent approximately $340 million of contract value to the Company.

As of the date of this press release, the Company's stabilized operating portfolio's critical load is 97.3% leased, CH1 is 9.5% leased and ACC5 is 57.3% pre-leased.

Liquidity On February 6, 2009, the Company closed on two loans totaling $30.0 million. Each loan has a one-year maturity date with options to extend the term up to four additional years, subject to customary conditions. Each loan is secured by development properties, ACC5 and SC1, and bears interest at a fixed rate of 12%.

The Company raised $150 million via the ACC4 accordion feature and paid off in entirety its CH1 construction loan on February 10, 2009, receiving proceeds net of the CH1 loan payoff of approximately $12 million.

With these transactions, the Company has no debt maturities until the third quarter of 2011 assuming the election of the extension options on the company's line of credit and new loans on ACC5 and SC1. As of the date of this press release, the Company has approximately $40 million of unrestricted cash and $10 million available on its revolving credit facility.

Development Update In the first quarter of 2009, the Company resumed development of ACC5 and estimates a completion date during the third quarter of 2009. The Company will spend approximately $30 to $40 million to complete this project. The Company's developments in New Jersey and Santa Clara remain temporarily suspended as it continues to work to obtain pre-leasing and financing in order to restart both developments. As of the date of this press release, total committed costs of approximately $37 million on NJ1 and SC1 remain accrued as construction costs payable, which will be paid over the next three quarters.

ABOUT OTCPICKS.COM OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at [email protected].

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability:Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated three thousand dollars by a third party for EUOK advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information: OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: [email protected] ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])).

Copyright ? 2009 M2 Communications Ltd.

[ Back To TMCnet.com's Homepage ]